indexado en
  • Abrir puerta J
  • Claves Académicas
  • InvestigaciónBiblia
  • Infraestructura Nacional de Conocimiento de China (CNKI)
  • Centro Internacional de Agricultura y Biociencias (CABI)
  • Búsqueda de referencia
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • CABI texto completo
  • Publón
  • Fundación de Ginebra para la Educación e Investigación Médica
  • Google Académico
Comparte esta página
Folleto de diario
Flyer image

Abstracto

Favipiravir: Promising Therapy for COVID-19

Amit Kumar Das*

COVID 19 is become one of the most threatened pandemics in recent time and spreading rapidly. Favipiravir, an antiviral drug, has shown promising but yet unproven effect against COVID-19 infection. Drug Controller General of India (DCGI) has recently approved Favipiravir for treating moderate to severe COVID-19 infected patients. Favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication and emerging as promising therapeutic potential as indicated by initial clinical studies. In this literature review author tries to summaries an overview of Favipiravir as a promising therapy for COVID-19 disease.